预约演示
FDA approves Merck’s WINREVAIR for pulmonary arterial hypertension
2024-03-27
临床3期上市批准快速通道临床结果突破性疗法
MSD’s WINREVAIR is intended to enhance patient exercise capacity and reduce PAH linked risks. Credit: Merck & Co., Inc. / Business Wire.
MSD US Food and Drug Administration (FDA) has granted approval to Merck & CoPAHSD)’s sotatercept-csrk,Merck & Co., Inc.nd name WINREVAIR, for the treatment of adults with pulmonary arterial hypertension (PAH).
It is tFood and Drug Administration (FDA)alling inhibitor therapy Merck & Cosotatercept-csrkWINREVAIRpulmonary arterial hypertension (PAH)
PAH is a rare progressive and life-threatening disease in which blood PAHsels in the lungs narrow and thicken, leading to a huge strain on the heart.
PAH treatment is indicated for use in PAH patients to improve exercise capacity, enhance WHO functional class and decrease the likelihood of worsening clinical events.
The therapy, which had already receivePAHreakthrough therapy designation from the FDA, works by re-instating the balance between pro and anti-proliferative signalling to regulate the vascular cell proliferation linked to PAH.
J&J’s nipocalimab gains FDA fast track status for FNAIT risk reduction
J&Jedanipocalimabgains JFDAnese approval for cTTP treatment
WINREVAIR is administered as a subcutaneous injection every three weeks.
The latesADZYNMAval is based on results from the STELLAR trial, a global, double-blind, placebo-controlled, multicentre, parallel-group Phase III study.
It involved 323 adult patients and examined the effects of WINREVAIR compared to placebo, both given along with standard background therapies.
WINREVAIR a significant 41m improvement in the six-minute walk distance from the baseline at week 24 when WINREVAIR was added to background therapy.
The treatment also substantially improved several secondary outcome measures, notably reducing morality or PAH clinical worsening event risks by 84% compared to background therapy alone.
The company will make WINREVAIR available through select spWINREVAIRpharmacies in the US by the end of next month.
Merck Research Laboratories global clinical development senior vice-president, head and chief medical offiWINREVAIRiav Barr stated: “PAH remains a debilitating disease with high morbidity and mortality.
“This approval of WINREVAIR is an important milestone and a testament to our science-led strategy and focusPAH the development of innovations that can help people affected by rare diseases like PAH.”
Earlier this month, MSD completed the acquisition of Harpoon Therapeutics to bolster its oncology pipeline.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。